Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
EPEupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc. (EPRX)

NASDAQ · Currency in USD
$6.87 ▼ -0.72 (-9.49%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.99 ▲ +0.12 (+1.75%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$7.59
Open
$7.61
Day's Range
$6.70 – $7.61
52 Week Range
$5.25 – $9.32
Volume
347,995
Avg. Volume
562,330
Market Cap
$453.92M
Beta (5Y Monthly)
1.50
PE Ratio (TTM)
--
EPS (TTM)
-$0.75
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$17.50

Profile: Eupraxia Pharmaceuticals Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
49
CEO
James A. Helliwell

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.26
DateEst.Actual
Aug 11, 2026-$0.23-$0.16Beat
May 12, 2026-$0.22-$0.23Miss
Mar 12, 2026-$0.16-$0.37Miss
Nov 4, 2025-$0.23-$0.19Beat
Aug 12, 2025-$0.21-$0.26Miss
May 6, 2025-$0.19-$0.21Miss

Analyst view

Consensus price target
$17.50 ▲ +154.7%
Range $11.00 – $25.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on EPRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.